Health Technology Assessment of Medical Devices in Korea

Sukyeong Kim PhD MPH BPharm
Senior Research Fellow, International Cooperation Advisor
Evidence-based Healthcare Research Department

Medical devices

- Less mature industry
  - Less experience preparing submission
  - Lower quality evidence (historically, and ethically)
- Less obvious patent protection
  - Short life cycle
  - Frequent functional, minor improvements
- Insufficient evidence fundamental
  - Pharmaceutical oriented researchers, experts
  - Data insufficiency (weaker surveillance system..)
Strong regulatory HTA

- nHTA introduced in 2006
  - Influenced by evidence-based medicine
  - Focusing on safety and effectiveness of newly introduced medical procedures
  - Systematic review for safety and effectiveness
  - Most of procedures are related to medical devices
  - After market approval, before NHI coverage
  - Delayed market access

- nHTA take almost 1 year after market approval

- MFDS : Ministry of Food and Drug Safety
- NECA : National Evidence-based Healthcare Collaborating Agency
- HIRA : Health Insurance Review & Assessment Service
One-stop system

- Parallel process of approval, nHTA, NHI coverage introduced in 2014
  - Improve patient accessibility by shorten process

Conditional use for evidence generation

- Introduced in 2013
  - Government supports health interventions for safety and effectiveness evidence generation
  - Urgent need for rare and severe diseases without alternative treatments
  - Only in designated hospitals during prescribed time period

<table>
<thead>
<tr>
<th>Technology</th>
<th>Period</th>
</tr>
</thead>
<tbody>
<tr>
<td>Therapeutic Use of Autologous Peripheral Blood Stem Cell in MI</td>
<td>2014.10–2017.09</td>
</tr>
<tr>
<td>Pancreatic Cancer Irreversible electroporation</td>
<td>2015.09–2018.08</td>
</tr>
<tr>
<td>PET-CT for C-11-Methionine</td>
<td>2016.08–2019.07</td>
</tr>
<tr>
<td>Autologous Platelet Rich Fluid for Vitreous body</td>
<td>2016.11–2019.10</td>
</tr>
<tr>
<td>Smart PreP2 BMAC to Diabetic Critical Limb Ischemia</td>
<td>2018.01–2020.12</td>
</tr>
<tr>
<td>Autologous Adipose-Derived Stem Cell Therapy</td>
<td>2018.05–2021.04</td>
</tr>
</tbody>
</table>
New policy for medical devices

- Fast tract for In Vitro Diagnostics
  - nHTA exemption
  - RWE generation
- Early dialogues from development to NHI coverage
  - Each stage with MFDS, NECA, and HIRA
- One-stop service system
  - Unified service team
  - Parallel process of regulatory review and nHTA
- R&D support for evidence generation

Challenges

- Scientific evidence for invasive medical devices
  - In debate
  - RWE generation and use system with strong research infrastructure and patient protection
  - Who will pay for RWE?
- International cooperation
  - Harmonization of regulatory affairs
  - HTA and research capacity building
Thank You!!